CARSON CITY, NV, Sept. 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc. (PHBI), a company specializing in the development of high quality tissue cultured starter plantlets for the cannabis and hemp industry, is pleased to provide another scientific development update. Since December 2019, the research and development company, Botanical Research In Motion Inc. (B.R.I.M.), has continued very successful growing trials with “CBD Dana” hemp strain, and, on March 19, 2020, submitted its data for strain registration to be listed on the List of Approved Cultivars (LOAC) in the European Union. Additionally, it is anticipated that the “CBD Dana” hemp strain will be submitted to Health Canada prior to end of, 2020 for listing on the Canadian list of approved cultivars (LOAC) status. Once listed, the significance of receiving the LOAC registration status for “CBD Dana” in Canada and the European Union will allow Pharmagreen to expand its sales of plantlets and its derived Cannabinoids oils to the largest CBD market in the world – the European Union as stated in the July 28, 2020 news release.

Once more ongoing research by B.R.I.M. has led to the development of its own scientific process and application for the production of feminized hemp seeds, in particular utilizing the proven “CBD Dana” strain.  This scientific process involves the production of pollen from the male plant that carries the X chromosome only without the use of any genetic modification processes.  While the female plant always carries the X chromosome the resulting combination due to natural pollination is XX thereby resulting in feminized seed only. This has huge significance for CBD hemp farmers as they only want female plants in their fields as they are the ones that produce the flowers from where the cannabinoids are derived either in oils or dried hemp buds.

This also adds another income stream opportunity for Pharmagreen as the company plans to produce tissue cultured plantlets, utilize B.R.I.M.’s newly developed technology to produce the FHS (Feminized Hemp Seed) for the global market, and also cultivate CBD Dana hemp strain for its high CBD and other cannabinoids content in its greenhouse(s) when built. 

B.R.I.M.’s research and development objective for Pharmagreen’s Cannabis Biotech Complex is to help protect and advance agriculture by providing proprietary, automated, and cost effective mass propagation technologies for production of disease-free plants using tissue culture techniques and other plant sciences for growers of today utilizing innovative technology in the cannabis space.

“B.R.I.M. science and research will be made available to Pharmagreen to exploit once the company is funded, builds its tissue culture complex and greenhouse(s) and receives its cannabis licence from Health Canada. Also pending U.S. Senate vote to federally legalize cannabis, to be held on September 21, 2020, the company will give serious consideration at building its facility in the U.S. We have many great opportunities ahead of us to really excel and we look forward to concluding our Chapter 11 process as soon as possible so we can move on with our ETN listing in Europe and get our construction financing under way,” concluded Peter Wojcik.

About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.

WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: PHBI) company.  WFS Pharmagreen Inc. is a tissue culture company that is becoming one of the largest producers of hemp plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally.  Pharmagreen’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same hemp plantlets with high Cannabinoids content and with less than 0.3% THC and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various plant species; for further information on the company progress on the construction of a 63,000 square foot “Tissue Culture Biotech Complex” please visit www.pharmagreen.ca

Safe Harbor Statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements. 

The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management. 

Contact Information:

www.pharmagreen.ca

Tel: (702) 803 9404

Email: info@pharmagreen.ca